# Enanta Pharmaceuticals to Present at The Citizens Life Sciences Conference
Canonical URL: https://biopharmsignal.com/news/ENTA/enanta-pharmaceuticals-to-present-at-the-citizens-life-sciences-conference
Ticker: ENTA
Company: Enanta Pharmaceuticals
Source: Enanta Pharmaceuticals
Published: 2026-03-03 12:00 EST
Original Source URL: https://ir.enanta.com
## Summary

WATERTOWN, Mass. --(BUSINESS WIRE)--Mar. 3, 2026-- Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases today announced that members of management will participate in a fireside

## Article Body
WATERTOWN, Mass. --(BUSINESS WIRE)--Mar. 3, 2026-- Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases today announced that members of management will participate in a fireside
## Recent Company News
- 2026-05-28 11:00 EST — [Enanta Pharmaceuticals to Present at the Jefferies Global Healthcare Conference](https://biopharmsignal.com/news/ENTA/enanta-pharmaceuticals-to-present-at-the-jefferies-global-healthcare-conference) — Source: Enanta Pharmaceuticals
- 2026-05-11 20:01 EST — [Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter Ended March 31, 2026](https://biopharmsignal.com/news/ENTA/enanta-pharmaceuticals-reports-financial-results-for-its-fiscal-second-quarter-ended-march-31-2026) — Source: Enanta Pharmaceuticals
- 2026-05-04 11:00 EST — [Enanta Pharmaceuticals to Present Data for its Respiratory Syncytial Virus and STAT6 Inhibitor Programs at the American Thoracic Society International Conference 2026](https://biopharmsignal.com/news/ENTA/enanta-pharmaceuticals-to-present-data-for-its-respiratory-syncytial-virus-and-stat6-inhibitor-programs-at-the-american-thoracic-society-international-conference-2026) — Source: Enanta Pharmaceuticals
- 2026-04-13 11:00 EST — [Enanta Pharmaceuticals Announces First Participant Dosed in Phase 1 Clinical Trial of EDP-978, an Oral, Once-Daily KIT Inhibitor, in Development for the Treatment of Urticaria](https://biopharmsignal.com/news/ENTA/enanta-pharmaceuticals-announces-first-participant-dosed-in-phase-1-clinical-trial-of-edp-978-an-oral-once-daily-kit-inhibitor-in-development-for-the-treatment-of-urticaria) — Source: Enanta Pharmaceuticals
- 2026-04-07 11:00 EST — [Enanta Pharmaceuticals to Present Data for Zelicapavir, an Oral, Once-Daily, N-Protein Inhibitor, in Development for the Treatment of Respiratory Syncytial Virus, at ESCMID Global 2026](https://biopharmsignal.com/news/ENTA/enanta-pharmaceuticals-to-present-data-for-zelicapavir-an-oral-once-daily-n-protein-inhibitor-in-development-for-the-treatment-of-respiratory-syncytial-virus-at-escmid-global-2026) — Source: Enanta Pharmaceuticals
## Related News
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)
- 2026-07-29 12:25 EST — ICCM — [IceCure: SIO Petitions NCCN to Include Cryoablation in Breast Cancer Treatment Guidelines, Citing IceCure's FDA Clearance  of ProSense®](https://biopharmsignal.com/news/ICCM/icecure-sio-petitions-nccn-to-include-cryoablation-in-breast-cancer-treatment-gu-bec46cd3)